(NASDAQ: PLYX) Polaryx Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 63.5%.
Polaryx Therapeutics's earnings in 2026 is -$6,849,000.On average, 5 Wall Street analysts forecast PLYX's earnings for 2026 to be -$11,015,964, with the lowest PLYX earnings forecast at -$11,723,778, and the highest PLYX earnings forecast at -$9,944,276. On average, 5 Wall Street analysts forecast PLYX's earnings for 2027 to be -$14,744,445, with the lowest PLYX earnings forecast at -$16,120,194, and the highest PLYX earnings forecast at -$13,607,956.
In 2028, PLYX is forecast to generate -$17,795,020 in earnings, with the lowest earnings forecast at -$19,051,139 and the highest earnings forecast at -$16,224,871.